Comparative proteomics of tumor and paired normal breast tissue highlights potential biomarkers in breast cancer

Cancer Genomics and Proteomics

Volumn 12, Issue 5, 2015, Pages 251-262

  Da Costa, Gustavo Goes ^a   Gomig, Talita Helen Bombardelli ^a   Kaviski, Rodrigo ^a   Sousa, Karla Santos ^a   Kukolj, Caroline ^a   De Lima, Rubens Silveira ^a,b   Urban, Cicero De Andrade ^b   Cavalli, Iglenir J ^a   Ribeiro, Enilze M S F ^a  

^a FEDERAL UNIVERSITY OF PARANÁ   (Brazil)

^b HOSPITAL NOSSA SENHORA DAS GRAÇAS   (Brazil)

Author keywords

Biomarker identification; Breast cancer; Differential expression; Proteome

Indexed keywords

ALPHA 1 ANTITRYPSIN; EPIDERMAL GROWTH FACTOR RECEPTOR 2; ESTROGEN RECEPTOR; GLUTATHIONE TRANSFERASE P1; HEAT SHOCK PROTEIN; PROGESTERONE RECEPTOR; SOLUBLE N ETHYLMALEIMIDE SENSITIVE FACTOR ATTACHMENT PROTEIN; TUMOR MARKER; VIMENTIN; PROTEOME;

ADULT; AGED; ARTICLE; BREAST CARCINOMA; CELL CYCLE PROGRESSION; CLINICAL ARTICLE; COMPARATIVE STUDY; CONTROLLED STUDY; FEMALE; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; ISOELECTRIC POINT; MASS SPECTROMETRY; MATRIX ASSISTED LASER DESORPTION IONIZATION TIME OF FLIGHT MASS SPECTROMETRY; MIDDLE AGED; MOLECULAR WEIGHT; POLYACRYLAMIDE GEL ELECTROPHORESIS; PROTEIN ANALYSIS; PROTEIN SUBUNIT; PROTEOMICS; TUMOR VOLUME; BREAST TUMOR; CANCER GRADING; MAMMARY GLAND; METABOLISM; PATHOLOGY; PROCEDURES;

ADULT; AGED; BIOMARKERS, TUMOR; BREAST NEOPLASMS; FEMALE; HUMANS; MAMMARY GLANDS, HUMAN; MIDDLE AGED; NEOPLASM GRADING; PROTEOME; PROTEOMICS; TUMOR BURDEN;

EID: 84943252936     PISSN: 11096535     EISSN: 17906245     Source Type: Journal    
DOI: None     Document Type: Article

References (93)

1. Coleman MP, Quaresma M, Berrino F, Lutz JM, De Angelis R, Capocaccia R, Baili P, Rachet B, Gatta G, Hakulinen T, Micheli A, Sant M, Weir HK, Elwood JM, Tsukuma H, Koifman S, Silva GA, Francisci S, Santaquilani M, Verdecchia A, Storm HH, Young JL and CONCORD Working Group: Cancer survival in five continents: a worldwide population-based study (CONCORD). Lancet Oncol 9(8): 730-756, 2008.
2. Instituto Nacional de Cancer Jose Alencar Gomes da Silva (INCA): Estimate/2014-Cancer Incidence in Brazil. 124p, 2014.
3. Howell A, Anderson AS, Clarke RB, Duffy SW, Evans DG, Garcia-Closas M, Gescher AJ, Key TJ, Saxton JM and Harvie MN: Risk determination and prevention of breastcancer. Breast Cancer Research 16(5): 446, 2014.
4. HondermarckH: Breast cancer: when proteomics challenges biological complexity. Mol Cell Proteomics 2(5): 281-291, 2003.
5. Gromov P, Moreira JM and Gromova I: Proteomic analysis of tissue samples in translational breast cancer research. Expert Rev Proteomics 11(3): 285-302, 2014.
6. Zeidan BA, Townsend PA, Garbis SD, Copson E and Cutress RI: Clinical proteomics and breast cancer. The Surgeon, 2015. Epub ahead of print.
7. Oliveira BM, Coorssen JR and Martins-de-Souza DJ: 2DE: the phoenix of proteomics. Proteomics 104: 140-150, 2014.
8. Rogowska-Wrzesinska A, Le Bihan MC, Thaysen-Andersen M andRoepstorff PJ: 2D gels still have a niche in proteomics. Proteomics 88: 4-13, 2013.
9. Rodrigo MA, Zitka O, Krizkova S, Moulick A, Adam V and Kizek R: MALDI-TOF MS as evolving cancer diagnostic tool: a review. J Pharm Biomed Anal 95: 245-255, 2014.
10. Bohm D, Keller K, Wehrwein N, Lebrecht A, Schmidt M, Kolbl H and Grus FH: Serum proteome profiling of primary breast cancer indicates a specificbiomarker profile. OncolRep 26(5): 1051-1056, 2011.
11. Lopez-Arias E, Aguilar-Lemarroy A, Felipe Jave-Suarez L, Morgan-Villela G, Mariscal-Ramirez I, Martinez-Velazquez M, Alvarez AH, Gutierrez-Ortega A and Hernandez-Gutierrez R: Alpha 1-antitrypsin: a novel tumor-associated antigen identified in patients with early-stage breast cancer. Electrophoresis 33(14): 2130-2137, 2012.
12. Qin XJ and Ling BX: Proteomic studies in breast cancer. Oncol Lett 3(4): 735-743, 2012.
13. Bradford MM: A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding. Anal Biochem 72: 248-254, 1976.
14. Costa GG, Kaviski R, Souza LE, Urban CA, Lima RS, Cavalli IJ and Ribeiro EM: Proteomic analysis of non-tumoral breast tissue. Genet Mol Res 10(4): 2430-2442, 2010.
15. Pucci-Minafra I, Cancemi P, Marabeti MR, Albanese NN, DiCara G, Taormina P and Marrazzo A: Proteomic profiling of 13 paired ductal infiltrating breast carcinomas and non tumoral adjacent counterparts. Proteomics Clin Appl 1: 118-129, 2007.
16. Pucci-Minafra I, Cancemi P, Fontana S, Minafra L, Feo S, Becchi M, Freyria AM and Minafra S: Expanding the proteincatalogue in the proteome reference map of human breast cancercells.Proteomics 6: 2609-2625, 2006.
17. Faulk WP, Hsi BL and Stevens PJ: Transferrin and transferrin receptors in carcinoma of the breast. The Lancet 2: 390-392, 1980.
18. Somiari RI, Sullivan A, Russell S, Somiari S, Hu H, Jordan R, George A, Katenhusen R, Buchowiecka A, Arciero C, Brzeski H, HookeJ and Shriver C: High-throughput proteomic analysis of human infiltrating ductal carcinoma of the breast. Proteomics 3(10): 1863-1873, 2003.
19. Mosesson MW: Fibrinogen and fibrin structure and functions.J Thromb Haemost 3(8): 1894-1904, 2005.
20. Jeong SH, Ko GH, Cho YH, Lee YJ, Cho BI, Ha WS, Choi SK, Kim JW, Lee CW, Heo YS, Shin SH, Yoo J and Hong SC: Pyrophosphatase overexpression is associated with cell migration, invasion, and poor prognosis in gastric cancer. Tumor Biol 33: 1889-1898, 2012.
21. Lexander H, Palmberg C, Auer G, Hellstrom M, Franzen B, Jornvall H and Egevad L: Proteomic analysis of protein expression in prostate cancer. Anal Quant Cytol Histol 27(5): 263-272, 2005.
22. Selicharova I, Smutna K, Sanda M, Ubik K, Matouskova E, Bursikova E, Brozova M, Vydra J and Jiracek J: 2 DE analysis of a new human cell line EM-G3 derived from breast cancer progenitor cells and comparison with normal mammary epithelial cells. Proteomics 7(9): 1549-1559, 2007.
23. Bhattacharya B, Prasad GL, Valverius EM, Salomon DS and Cooper HL: Tropomyosins of human mammary epithelial cellsconsistent defects of expression in mammary carcinoma cell lines. Cancer Research 50(7): 2105-2112, 1990.
24. Franzen B, Linder S, Alaiya AA, Eriksson E, Uruy K, Hirano T, Okuzawa K and Auer G: Analysis of polypeptide expression in benign and malignant human breast lesions down-regulation of cytokeratins. British Journal of Cancer 74(10): 1632-1638, 1996.
25. Kabbage M, Trimeche M, Bergaoui S, Hammann P, Kuhn L, Hamrita B, ben Nasr H, Chaieb A, Chouchane L and Chahed K: Calreticulin expression in infiltrating ductal breast carcinomas: relationships with disease progression and humoral immune responses.TumourBiol 34(2): 1177-1188, 2013.
26. Carvalho CMS: Analise da expressao genica de Tropomiosinas em carcinomas mamarios. Master Dissertation. Genetics Post Graduation Program, Genetics Department, Federal University of Parana. 2013.
27. Alldridge L, Metodieva G, Greenwood C, Al Janabi K, Thwaites L, Sauven P and Metodiev M: Proteome profiling of breast tumors by gel electrophoresis and nanoscale electrospray ionization mass spectrometry. J Proteome Res 7(4): 1458-1469, 2008.
28. Huang TC, Chang HY, Hsu CH, Kuo WH, Chang KJ and Juan HF: Targeting therapy for breast carcinoma by ATP synthase inhibitor aurovertin B. J Proteome Res 7: 1433-1444, 2008.
29. Sutton CW, Rustogi N, Gurkan C, Scally A, Loizidou MA, Hadjisavvas A and Kyriacou K: Quantitative proteomic profiling of matched normal and tumor breast tissues.J Proteome Res. 9(8): 3891-3902, 2010.
30. Deng SS, Xing TY, Zhou HY,Xiong RH, Lu YG, Wen B, Liu SQ and Yang HJ: Comparative proteome analysis of breast cancer and adjacent normal breast tissues in human. Genomics Proteomics Bioinformatics 4(3): 165-172, 2006.
31. Ebert MP, Kruger S, Fogeron ML, Lamer S, Chen J, Pross M,Schulz HU, Lage H, Heim S,Roessner A, Malfertheiner P and Rocken C: Overexpression of cathepsin B in gastric cancer identified by proteome analysis. Proteomics 5: 1693-1704, 2005.
32. Perroud B, Lee J, Valkova N, Dhirapong A, Lin PY, Fiehn O,Kultz D and Weiss RH: Pathway analysis of kidney cancer usingproteomics and metabolic profiling. Mol Cancer 5: 64, 2006.
33. Huang Q, Huang Q, Lin W, Lin J and Lin X: Potential roles for PA28beta in gastric adenocarcinoma development and diagnosis. J Cancer Res ClinOncol 136: 1275-1282, 2010.
34. Wulfkuhle JD, Sgroi DC, Krutzsch H, McLean K, McGarvey K, Knowlton M, Chen S, Shu H, Sahin A, Kurek R, Wallwiener D, Merino MJ, Petricoin EF 3rd, Zhao Y and Steeg PS: Proteomics of human breast ductal carcinoma in situ. Cancer Res 62(22): 6740-6749, 2002.
35. Kang S, Kim MJ, An H, Kim BG, Choi YP, Kang KS, Gao MQ, Park H, Na HJ, Kim HK, Yun HR, Kim DS and Cho NH: Proteomic molecular portrait of interface zone in breast cancer. J Proteome Res 9(11): 5638-5645, 2010.
36. Fritz G, Brachetti C, Bahlmann F, Schmidt M andKaina B: Rho GTPases in human breast tumours: expression and mutation analyses and correlation with clinical parameters. Br J Cancer 87(6): 635-644,2002.
37. Moon HG, Jeong SH, Ju YT, Jeong CY, Lee JS, Lee YJ, Hong SC, Choi SK, Ha WS, Park ST and Jung EJ: Up regulation of RhoGDI2 in human breast cancer and its prognostic implications. Cancer Res Treat 42(3): 151-156, 2010.
38. Ramos FS, Serino LTR, Carvalho CMS, Lima RS, Urban CA, Cavalli IJ and Ribeiro EMSF: PDIA3 and PDIA6 genes expression as an aggressiveness marker in primary ductal breast cancer. Genet Mol Res, 2015. In Press.
39. Song MN, Moon PG, Lee JE, Na M, Kang W, Chae YS, Park JY, Park H and Baek MC: Proteomic analysis of breast cancer tissues to identify biomarker candidates by gel assisted digestion and label free quantification methods using LC MS/MS. Arch Pharm Res 35(10): 1839-1847, 2012.
40. Song Y, Yang Z, Ke Z, Yao Y, Hu X, Sun Y, Li H, Yin J and Zeng C: Expression of 14-3-3γ in patients with breast cancer: correlation with clinicopathological features and prognosis. Cancer Epidemiol 36(6): 533-536, 2012.
41. Li N, Wang H, Fan J, Tong C, Yang J, Wei H, Yi J and Ling R: Overexpression of 14-3-3? promotes tumor metastasis and indicates poor prognosis in breast carcinoma. Oncotarget 5(1): 249-257, 2014.
42. Lapillonne A, Coue O, Friederich E, Nicolas A, Del Maestro L, Louvard D, Robine S and Sastre Garau X: Expression patterns of L plastin isoform in normal and carcinomatous breast tissues. Anticancer Res 20(5A): 3177-3182, 2000.
43. Carcoforo P, Ura B, Mischiati C, Squerzanti M, Lanzara V, Cervellati C, Calza R, De Laureto PP, Frare E, Portinari M, Feriotto G, Lanzara S, Agostinelli E and Bergamini CM: Comparative proteomic analysis of ductal breast carcinoma demonstrates an altered expression of chaperonins and cytoskeletal proteins. Mol Med Rep 7(5): 1700-1704, 2013.
44. Hudelist G, Singer CF, Pischinger KI, Kaserer K, Manavi M, Kubista E and Czerwenka KF: Proteomic analysis in human breast cancer: identification of a characteristic protein expression profile of malignant breast epithelium. Proteomics 6(6): 1989-2002, 2006.
45. Grzegrzolka J, Kurnol K, Piotrow P, Pula B, Kobierzycki C, Piotrowska A, Jablonska K, Wojnar A, RysJ, Dziegiel P and Podhorska Okolow M: Hsp-27 expression in invasive ductal breast carcinoma. Folia HistochemCytobiol 50(4): 527-533, 2012.
46. Noh DY, Ahn SJ, Lee RA, Kim SW, Park IA and Chae HZ: Overexpression of peroxiredoxin in human breast cancer. Anticancer Res 21: 2085-2090, 2001.
47. Karihtala P, Mantyniemi A, Kang SW, Kinnula VL and Soini Y:Peroxiredoxins in breast carcinoma. Clin Cancer Res 9: 3418-3424, 2003.
48. Chua PJ, Lee EH, Yu Y, Yip GW, Tan PH and Bay BH: Silencing the Peroxiredoxin III gene inhibits cell proliferation in breast cancer. Int J Oncol 36(2): 359-364, 2010.
49. Niu Y, Liu T, Tse GM, Sun B, Niu R, Li HM, Wang H, Yang Y, Ye X, Wang Y, Yu Q and Zhang F.Increased expression of centrosomal alpha, gamma tubulin in atypical ductal hyperplasia and carcinoma of the breast. Cancer Sci 100(4): 580-587, 2009.
50. Liu CY, Lin HH, Tang MJ and Wang YK: Vimentin contributes to epithelial mesenchymal transition cancer cell mechanics by mediating cytoskeletal organization and focal adhesion maturation. Oncotarget 2015. Epub ahead of print.
51. Satelli A and Li S: Vimentin in cancer and its potential as amolecular target for cancer therapy. Cell Mol Life Sci 68: 3033-3046, 2011.
52. Milioli HH, Santos Sousa K, Kaviski R, Dos Santos Oliveira NC, De Andrade Urban C, De Lima RS, Cavalli IJ and De Souza Fonseca Ribeiro EM: Comparative proteomics of primary breast carcinomas and lymph node metastases outlining markers of tumor invasion. Cancer Genomics Proteomics 12(2): 89-101, 2015.
53. Krajewska M, Kim H, Shin E, Kennedy S, Duffy MJ, Wong YF, Marr D, Mikolajczyk J, Shabaik A, Meinhold Heerlein I, Huang X, Banares S, Hedayat H, Reed JC and Krajewski S: Tumor associated alterations in caspase 14 expression in epithelial malignancies. Clin Cancer Res 11(15): 5462-5471, 2005.
54. Helfman DM, Flynn P, Khan P and Saeed A: Tropomyosin as a Regulator of Cancer Cell Transformation. Advances in Experimental Medicine and Biology 644: 124 131, 2008.
55. Asselin Labat ML, Sutherland KD, Vaillant F, Gyorki DE, Wu D, Holroyd S, Breslin K, Ward T, Shi W, Bath ML, Deb S, Fox SB, Smyth GK, Lindeman GJ and Visvader JE: Gata-3 negatively regulates the tumor-initiating capacity of mammary luminal progenitor cells and targets the putative tumor suppressor caspase 14. Mol Cell Biol 31(22): 4609-4622, 2011.
56. Giri A, Bajpai S, Trenton N, Jayatilaka H, Longmore GD and Wirtz D: The Arp2/3 complex mediates multigeneration dendritic protrusions for efficient 3 dimensional cancer cell migration. FASEB J 27(10): 4089-4099, 2013.
57. LeNaour F, Misek DE, Krause MC, Deneux L, Giordano TJ, Scholl S and Hanash SM: Proteomics based identification of RS/DJ 1 as a novel circulatingtumor antigen in breast cancer. Clin Cancer Res 7: 3328-3335, 2001.
58. Ismail IA, Kang HS, Lee HJ, Kim JK and Hong SH: DJ-1 upregulates breast cancer cell invasion by repressing KLF17 expression. Br J Cancer 110(5): 1298-1306, 2014.
59. Matsushima S, Mori M, Adachi Y, Matsukuma A and Sugimachi K: S100 protein positive human breast carcinomas: an immunohistochemical study. J SurgOncol 55: 108-113, 1994.
60. Nesland J, Holm R, Johannessen J and Gould V: Neuron specific enolase immunostaining in the diagnosis of breast carcinomas with neuroendocrine differentiation. Its usefulness and limitations. J Pathol 148: 35-43,1986.
61. Kirillina MP, Loskutova KS, Innokent'eva AS, Lushnikova EL and Nepomnyashchikh LM: Immunohistochemical reactions of primary neuroendocrine breast cancer. Bull ExpBiol Med 158(3): 368-370, 2015.
62. Shim DH, Lim JW and Kim H: Differentially expressed proteins in nitric oxide stimulated NIH/3T3 fibroblasts: implications for inhibiting cancer development. Yonsei Med J 56(2): 563-571, 2015.
63. Renz M, Betz B, Niederacher D, Bender HG and Langowski J: Invasive breast cancer cells exhibit increased mobility of the actin binding protein CapG. Int J Cancer 122(7): 1476-1482, 2008.
64. Murata S, Yashiroda H and Tanaka K: Molecular mechanisms of proteasome assembly. Nat Rev Mol Cell Biol 10(2): 104-115, 2009.
65. Stoneley M and Willis AE: eIF4A1 is a promising new therapeutic targetin ER negative breast cancer. Cell Death and Differentiation 22: 524-525, 2015.
66. Modelska A, Turro E, Russell R, Beaton J, Sbarrato T, Spriggs K, Miller J, Graf S, Provenzano E, Blows F, Pharoah P, Caldas C and Le Quesne J: The malignant phenotype in breast cancer is driven by eIF4A1 mediated changes in the translational landscape. Cell Death Dis 6: e1603, 2015.
67. Balasubramani M, Day BW, Schoen RE and Getzenberg RH: Altered expression and localization of creatine kinase B, heterogeneous nuclear ribonucleoprotein F, and high mobility group box 1 protein in the nuclear matrix associated with colon cancer. Cancer Res 66(2): 763-769, 2006.
68. Khan R, Zahid S, Wan YJ, Forster J, Karim AB, Nawabi AM, Azhar A, Rahman MA and Ahmed N: Protein expression profiling of nuclear membrane protein reveals potential biomarker of human hepatocellular carcinoma. Clin Proteomics 10(1): 6, 2013.
69. Liang S, Singh M and Gam LH: The Differential Expression of Aqueous Soluble Proteins inBreast Normal and Cancerous Tissues in Relation to Stage and Grade of Patients. J Biomed Biotechnol 2010: 5164-5169, 2010.
70. Silacci P, Mazzolai L, Gauci C, Stergiopulos N, Yin HL and Hayoz D: Gelsolin superfamily proteins: key regulators of cellular functions. Cell Mol Life Sci 61: 2614-2623, 2004.
71. Witke W, Li W, Kwiatkwoski DJ and Southwick FS: Comparisons of CapG and gelsolin-nullmacrophages: demonstration of a unique rolefor CapG in receptor mediated ruffling, phagocytosis, and vesiclerocketing. J Cell Biol 154: 775-784, 2001.
72. Coulombe PA and Wong P: Cytoplasmic intermediate filaments revealed as dynamic and multipurpose scaffolds. Nat Cell Biol 6: 699-706, 2004.
73. Mannello F, Tonti GA, Simone P, Ligi D and Medda V: Ironbinding proteins and C reactive protein in Nipple Aspirate Fluids: role of Iron driven inflammation in breast cancer microenvironment? Am J Transl Res 3(1): 100-113, 2011.
74. van CampenhoutA, van Campenhout CM, Lagrou AR and Manuel y Keenoy B: Transferrin modifications and lipid peroxidation: Implications in diabetes mellitus. Free Radic Res 37(10): 1069-1077, 2003.
75. Rice Evans C: Oxidised low density lipoproteins. In: Free Radicals-From Basic Science to Medicine. Poli, G, Albano E and Dianzani MU(eds.). Basek, Birkhauser, pp. 323-339, 1993.
76. Gomme PT, McCann KB and Bertolini J: Transferrin: structure, function and potential therapeutic actions. Drug Discov Today 10(4): 267-273, 2005.
77. Tomson BN and Arndt KM: The many roles of the conserved eukaryotic Paf1 complex inregulating transcription, histone modifications, and diseasestates. Biochim Biophys Acta 1829(1): 116-126, 2013.
78. Thomas LR, Wang Q, Grieb BC, Phan J, Foshage AM, Sun Q, Olejniczak ET, Clark T, Dey S, Lorey S, Alicie B, Howard GC, Cawthon B, Ess KC, Eischen CM, Zhao Z, Fesik SW and Tansey WP: Interaction with WDR5 Promotes Target Gene Recognition and Tumorigenesis by MYC. Mol Cell 58(3): 440-452, 2015.
79. Helfman DM, Flynn P, Khan P and Saeed A: Tropomyosin as a Regulator of Cancer Cell Transformation. Advances in Experimental Medicine and Biology 644: 124-131, 2008.
80. Zhu S, Si ML, Wu H and Mo YY: MicroRNA 21 targets the tumor suppressor gene tropomyosin 1 (TPM1). J Biol Chem 282(19): 14328-14336, 2007.
81. Wilkinson B and Gilbert HF: Protein disulfide isomerase. Biochim Biophys Acta 1699(1-2): 35-44, 2004.
82. Leys CM, Nomura S, Lafleur BJ, Ferrone S, Kaminishi M, Montgomery E, Goldenring JR: Expression and prognostic significance of prothymosin alpha and ERp57 in human gastric cancer. Surgery 141(1): 41-50, 2007.
83. Pressinotti NC, Klocker H, Schafer G, DucLuu V, Luuruschhaupt M, Kuner R, Steiner E, Poustka A, Bartsch G and Sultmann H: Differential expression of apoptotic genes PDIA3 and MAP3K5 distinguishes between low and high risk prostate cancer. Molecular Cancer 1: 63-71, 2009.
84. Ayshamgul H, Ma H, Ilyar S, Zhang LW and Abulizi A: Association of defective HLA I expression with antigen processing machinery and their association with clinicopathological characteristics in Kazak patients with esophageal cancer. Chinese Medical Journal 124(3): 341-346, 2011.
85. Kołodziejczyk J and Ponczek MB: The role of fibrinogen, fibrinand fibrin(ogen) degradation products(FDPs) in tumor progression. Wspolczesna Onkol 17(2): 113-119, 2013.
86. Mishra DR, Chaudhary S, Krishna BM and Mishra SK: Identification of critical elements for regulation of Inorganic Pyrophosphatase (PPA1) in MCF7 Breast Cancer Cells. PLoS One 10(4): e0124864, 2015.
87. Hamrita B, Chahed K, Trimeche M, Guillier CL, Hammann P, Chaieb A, Korbi S and Chouchane L: Proteomics based identification of alpha1 antitrypsin and haptoglobin precursors as novel serum markers in infiltrating ductal breast carcinomas.Clin Chim Acta 404(2): 111-118, 2009.
88. Luo Y, Zhang J, Liu Y, Shaw AC, Wang X, Wu S, Zeng X, Chen J, Gao Y and Zheng D: Comparative proteome analysis of breast cancer and normal breast. Mol Biotechnol 29(3): 233-244, 2005.
89. Flynn A and Proud CG: The role of eIF4 in cell proliferation. Cancer Surv 27: 293-310, 1996.
90. Xia D, Esser L, Tang WK, Zhou F, Zhou Y, Yu L and Yu CA: Structural analysis of cytochrome bc1 complexes: implications to the mechanism of function. Biochim Biophys Acta 1827(11-12): 1278-1294, 2013.
91. Won KA, Schumacher RJ, Farr GW, Horwich AL and Reed SI: Maturation of human cyclin E requires the function of eukaryotic chaperonin CCT. Mol Cell Biol 18: 7584-7589, 1998.
92. Hansen,WJ, Ohh M, Moslehi J, Kondo K, Kaelin WG and Welch WJ: Diverse effects of mutations in exon II of the von Hippel Lindau (VHL) tumor suppressor gene on the interaction of pVHL with the cytosolic chaperonin and pVHL dependent ubiquitin ligase activity. Mol Cell Biol 22: 1947-1960, 2002.
93. Boudiaf Benmammar C, Cresteil T and Melki R: The cytosolic chaperonin CCT/TRiC and cancer cell proliferation. PLoS One 8(4): e60895, 2013.